August 30th, 2017 – Vancouver, BC –Isodiol International Inc. (CSE: ISOL) (OTC: LAGBF) (FSE: LB6A.F) (the “Company” or “Isodiol”) a global cannabinoid innovator specializing in the development of pharmaceutical and consumer products announces it has signed a distribution partnership with FarmaUSA™, a leading global wholesale distributor of imported pharmaceutical products in South America. This is the latest action taken by the Company to further secure its position in the Brazilian market and provide for an additional expansion into greater South America.
This deal will expand Isodiol’s product Isoderm™ in Brazil and across South America by utilizing FarmaUSA’s existing distribution and doctor network to increase the presence of Isoderm™ Direct Effect Technologies™. FarmaUSA will facilitate physician conferences across the country to further educate healthcare professionals on the benefits of Isoderm™ while continuing to work with regulatory officials at Agência Nacional de Vigilância Sanitária (ANVISA) for commencing a clinical trial.
Marcos Agramont, CEO of Isodiol International Inc. stated, “This is a major milestone in the development of our international expansion strategy. FarmaUSA is very well respected among healthcare professionals in South America to help facilitate this process for the Company. I anticipate a dramatic increase in the amount of prescriptions being written by physicians in these markets as we move forward and head towards a clinical trial in the coming months.”
Djalma Nogueira, CEO of FarmaUSA stated, “We are very excited to work with Isodiol in bringing Isoderm™ to the South American market. We have seen a tremendous initial response from the health professionals who have commenced prescribing the product and we anticipate this to continue. With our Isodiol partnership now established, we are well positioned to enter additional markets in South America and become the leader in the space.”
About Isodiol International Inc.
Isodiol International Inc. is the market leader in pharmaceutical and nutraceutical grade phytochemical compounds and the industry leader in the manufacturing and development of phytoceutical consumer products.
Isodiol is the pioneer of many firsts for the cannabis industry including commercialization of a 99%+ pure pharmaceutical grade cannabinoid crystalline isolate derived from exempt parts of the hemp plant, micro-encapsulations, and nanotechnology for the highest quality consumable and topical skin care products.
Isodiol’s growth strategy includes the development of over-the-counter and pharmaceutical drugs, expanding its phytoceutical portfolio and will aggressively continue international expansion into Latin America, Asia and Europe.
ON BEHALF OF THE BOARD
“Marcos Agramont” CEO & Director
Forward-Looking Information: This news release contains “forward-looking information” within the meaning of applicable securities laws relating to statements regarding the Company’s business, products and future the Company’s business, its product offerings and plans for sales and marketing. Although the Company believes that the expectations reflected in the forward looking information are reasonable, there can be no assurance that such expectations will prove to be correct. Readers are cautioned to not place undue reliance on forward-looking information. Such forward looking statements are subject to risks and uncertainties that may cause actual results, performance and developments to differ materially from those contemplated by these statements depending on, among other things, the risks that the Company’s products and plan will vary from those stated in this news release and the Company may not be able to carry out its business plans as expected. Except as required by law, the Company expressly disclaims any obligation, and does not intend, to update any forward looking statements or forward-looking information in this news release. Although the Company believes that the expectations reflected in the forward looking information are reasonable, there can be no assurance that such expectations will prove to be correct and makes no reference to profitability based on sales reported. The statements in this news release are made as of the date of this release.
The CSE has not reviewed, approved or disapproved the content of this press release.